Cytarabine hydrochloride

• CAT Number: I004619
• CAS Number: 69-74-9
• Molecular Formula: C9H14ClN3O5
• Molecular Weight: 279.68
• Purity: ≥95%
• Synonyms: 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;hydrochloride
• Target: DNA Synthesis
• Solubility: 10 mM in DMSO
• Storage: Store at -20C

Cytarabine hydrochloride (CAT: I004619), also known as cytosine arabinoside or Ara-C, is a chemotherapy medication used in the treatment of various types of cancer, particularly leukemia. It is a nucleoside analog that inhibits DNA synthesis by incorporating into DNA strands and interfering with their replication. Cytarabine is primarily used in the treatment of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and certain types of lymphoma. It may be administered intravenously or subcutaneously, depending on the specific treatment regimen. Cytarabine can cause various side effects, including myelosuppression, gastrointestinal disturbances, and neurotoxicity. Close monitoring and proper supportive care are important during treatment with cytarabine.

Reference

[1]. Tobias, S.C. and R.F. Borch, Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol Pharm, 2004. 1(2): p. 112-6.
[2]. Besirli, C.G., et al., Cytosine arabinoside rapidly activates Bax-dependent apoptosis and a delayed Bax-independent death pathway in sympathetic neurons. Cell Death Differ, 2003. 10(9): p. 1045-58.
[3]. Yamauchi, H., et al., Involvement of p53 in 1-beta-D-arabinofuranosylcytosine-induced trophoblastic cell apoptosis and impaired proliferation in rat placenta. Biol Reprod, 2004. 70(6): p. 1762-7.
[4]. Richel, D.J., et al., Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia. Br J Cancer, 1988. 58(6): p. 730-3.